US Corporate Distress Financial Stress SEC Filings — March 04, 2026

04-03-2026

Ziff Davis, Inc. and its subsidiary Ziff Davis, LLC entered into a Securities Purchase Agreement dated March 2, 2026, to sell all outstanding equity interests in specified Transferred Entities (listed on Schedule I) and related Irish assets to Accenture Inc., subject to customary closing conditions and adjustments outlined in Section 2.2. The agreement includes ancillary documents such as an Irish Asset Purchase Agreement, Transition Services Agreement, Escrow Agreement, and employment agreements for Key Employees effective upon closing. No financial performance metrics or period-over-period comparisons are provided in the filing.

• ·Agreement executed on March 2, 2026; SEC 8-K filed March 4, 2026.
• ·Involves Irish Seller and Specified Irish Assets via separate Irish Asset Purchase Agreement (Exhibit A).
• ·Key Employees (listed in Purchaser Disclosure Schedule Section 1.1(a)) have executed employment agreements conditioned on closing.
• ·Closing subject to conditions in Article IX, including regulatory approvals and no material adverse changes.

04-03-2026

Alliant Energy Corporation entered into a $400M Credit Agreement dated March 2, 2026, with U.S. Bank National Association as Administrative Agent and CoBank, ACB; Mizuho Bank, Ltd.; and TD Securities (USA) LLC as Joint Lead Arrangers and Joint Book Runners. The facility provides an Aggregate Commitment of $400M, with Applicable Margins of 0.00% for Base Rate Borrowings and 0.85% for Term SOFR Borrowings. No prior period comparisons are available as this is a new financing arrangement.

• ·Filing Date: March 04, 2026
• ·Agreement effective date: March 2, 2026
• ·Alternate Base Rate defined as highest of zero, Prime Rate, Federal Funds Effective Rate + 0.50%, or Term SOFR (1-month) + 1.00%

04-03-2026

Charles & Colvard, Ltd. filed a voluntary Chapter 11 bankruptcy petition on March 2, 2026, in the United States Bankruptcy Court for the Eastern District of North Carolina, planning to operate as a debtor in possession while seeking first-day relief for employee wages, vendor payments, insurance, and taxes. The filing may trigger defaults under key agreements, including a Convertible Secured Note with Ethara Capital LLC and a lease with SBP Office Owner, L.P., potentially accelerating obligations though stayed under bankruptcy law. The company cautions that trading in its common stock is highly speculative, with shareholders facing significant or complete loss depending on the Chapter 11 outcome.

• ·Petition Date: March 2, 2026
• ·News release issued: March 3, 2026 (Exhibit 99.1)
• ·Convertible Secured Note Purchase Agreement dated June 24, 2025
• ·Lease Agreement dated December 9, 2013 (amended December 23, 2013, April 15, 2014, January 29, 2021)
• ·Investor relations website: https://ir.charlesandcolvard.com

04-03-2026

Enhabit, Inc. entered into an Amended and Restated Credit Agreement dated February 26, 2026, which amends and restates the existing Credit Agreement dated June 1, 2022. Wells Fargo Bank, National Association serves as Administrative Agent, Collateral Agent, and Swingline Lender, with multiple banks including BofA Securities, Inc., Capital One, N.A., Regions Bank, JPMorgan Chase Bank, N.A., and Citizens Bank, N.A. acting as Joint Lead Arrangers and Joint Bookrunners. The agreement outlines standard terms for commitments, loans, borrowings, and covenants, with no specific facility sizes or rates detailed in the provided excerpt.

• ·Existing Credit Agreement originally dated June 1, 2022.
• ·SEC 8-K Filing Date: March 04, 2026.
• ·Items reported: 1.01 (Entry into Material Definitive Agreement), 2.03 (Creation of Direct Financial Obligation), 9.01 (Financial Statements and Exhibits).

04-03-2026

Rise Gold Corp. entered a strategic 18-month development partnership with Morgan Hughes Energy to advance the Idaho-Maryland Mine as a gold and critical-minerals project, issuing 18 million warrants at $0.40 strike price and offering a potential $1.5M milestone payment upon securing capital commitments. Morgan Hughes will support planning, capital formation, and positioning within U.S. critical-minerals initiatives. However, the company faces ongoing regulatory hurdles, including a denied Use Permit by Nevada County Supervisors and a pending Writ of Mandamus with oral arguments on March 6, 2026.

• ·Warrants vest in tranches: 9M on critical-minerals framework advancement, 4.5M on development support, 4.5M on capital commitments.
• ·Morgan Hughes board seat upon qualifying milestone if maintaining 5% ownership.
• ·Alternative to reimbursement: 1.8M warrants for 12 months upon mutual agreement.
• ·I-M Mine historical grades: gold 0.50 oz/ton (17.1 g/t), no domestic U.S. tungsten mine since 2015.
• ·Writ of Mandamus filed May 2024 challenging denial of Use Permit and vested rights.

04-03-2026

Babcock & Wilcox reported Q4 2025 revenue of $161.0 million, essentially flat YoY compared to $161.8 million, but delivered strong profitability with operating income of $12.2 million (up from $2.6 million) and Adjusted EBITDA of $16.4 million (53% increase from $10.7 million). Full year 2025 revenue increased slightly by 1.2% to $587.7 million alongside a 107% surge in Adjusted EBITDA to $43.7 million, though the company still recorded a $32.8 million loss from continuing operations (improved from $104.3 million prior year). Key highlights include signing full notice to proceed on a $2.4 billion AI data center project with Base Electron, boosting continuing operations backlog to $2.8 billion (470% YoY increase) and reducing net debt to $119.7 million.

• ·Paid off outstanding bonds due February 2026 in December 2025; plans to pay off December 2026 bonds in 2026.
• ·Earnings conference call scheduled for March 16, 2026 at 5 p.m. ET.
• ·Extended maturity date of Axos facility.

04-03-2026

SSR Mining Inc. entered a binding memorandum of understanding to sell its 80% ownership in the Çöpler mine and related properties to Cengiz Holding A.S. for $1.5B in cash, payable at closing, with a $100M deposit and $50M reciprocal break fee. The transaction excludes the Hod Maden development project, is expected to close in Q3 2026 subject to Turkish regulatory approvals and limited due diligence, and is deemed fair by CIBC's fairness opinion. Proceeds will fund reinvestment, capital returns, and growth, repositioning the portfolio toward Americas operations including the Cripple Creek & Victor mine.

• ·Fairness opinion issued by CIBC World Markets Inc. on March 3, 2026
• ·Transaction not subject to financing contingency or operational permits
• ·Legal advisors: Allen Overy Shearman Sterling LLP
• ·Expected closure: third quarter of 2026
• ·SSR Mining retains 20% interest in Hod Maden project

04-03-2026

On March 3, 2026, the NYSE suspended trading in Vicarious Surgical Inc.'s Class A common stock (RBOT) after determining the company's average global market capitalization fell below the $15M threshold over a consecutive 30 trading day period under Section 802.01B, and commenced delisting proceedings via Form 25 following any appeal. The company is evaluating an appeal within 10 business days and has approval to quote on the OTCID market tier starting March 4, 2026, but this shift to a less liquid OTC market is expected to depress the stock price, reduce liquidity, limit equity financing access, and impair employee equity incentives. No positive financial metrics or performance improvements were reported.

• ·Appeal of delisting determination must be filed within 10 business days of March 3, 2026 notification.
• ·Company headquartered at 78 Fourth Avenue, Waltham, MA 02451.

04-03-2026

Edible Garden AG Incorporated entered into a Note Purchase Agreement dated March 3, 2026, with Streeterville Capital, LLC, issuing a secured promissory note with $1.625M principal for a $1.5M purchase price, incorporating a $120K original issue discount and $5K transaction expenses. The note is secured by all company assets (excluding Tetra Pak-related property) and guaranteed by subsidiaries 2900 Madison Ave Holdings, LLC and Edible Garden Corp., providing immediate cash influx but imposing restrictive covenants limiting future debt, equity issuances, and liens. While offering liquidity, the high OID signals elevated financing costs amid ongoing obligations.

• ·Closing Date: March 3, 2026, via electronic signatures at offices in Lehi, Utah
• ·Collateral excludes all assets, equipment, or property purchased from Tetra Pak, Inc. (including replacements and proceeds)
• ·Covenants restrict Restricted Issuances, new liens (except Tetra Pak assets), subsidiary equity/debt changes, and require timely SEC filings and listing maintenance on NYSE/Nasdaq American

04-03-2026

On March 3, 2026, Hexcel Corporation entered into a Cooperation Agreement with Vision One Fund, LP and affiliates, appointing Neal J. Keating to the Board of Directors and Audit Committee, nominating him for the 2026 Annual Meeting, and limiting Board size to 10 directors until the 2026 Annual Meeting and 9 thereafter until the Expiration Date. Vision One Parties agreed to withdraw their 2026 Annual Meeting nominees, adhere to standstill restrictions, and vote for Board nominees. No financial terms or impacts were disclosed.

• ·Board size limited to no more than 10 directors until 2026 Annual Meeting and 9 directors from 2026 Annual Meeting until Expiration Date (earlier of 30 days prior to 2027 stockholder nomination deadline or 150 days prior to 2026 Annual Meeting one-year anniversary).
• ·Neal J. Keating, age 70, previously Chairman, President, and CEO of Kaman Corporation (2008-2020), Executive Chairman until 2021; COO of Hughes Supply; CEO of GKN Aerospace.
• ·Mr. Keating serves on Hubbell Incorporated board since 2010 (chairs nominating/governance committee); former lead director of Triumph Group (2022-July 2025) and Barnes Group Inc. (2023-2025).
• ·No arrangements or understandings other than Cooperation Agreement for appointment; no reportable related party transactions under Item 404(a).

04-03-2026

Tevogen Bio Holdings Inc. adopted a Certificate of Amendment to its Certificate of Incorporation, authorizing a 1-for-50 reverse stock split of its common stock, effective March 6, 2026, at 12:01 a.m. ET, with no fractional shares issued and cash payments in lieu thereof. Authorized capital stock remains 820M total shares, comprising 800M common shares and 20M preferred shares, each with $0.0001 par value. The amendment was approved by the Board and stockholders without changes to other sections.

• ·Reverse split applies automatically without further action by holders.
• ·Filed with Delaware Secretary of State; executed March 3, 2026.

04-03-2026

Azenta, Inc. (AZTA) completed the strategic acquisition of UK Biocentre Limited through its subsidiary Azenta UK Ltd for total consideration of GBP 20.5 million net of cash, inclusive of up to GBP 1.8 million in contingent consideration. UK Biocentre, which generated GBP 15.3 million in revenue over the twelve months ending September 30, 2025, will operate as a European hub to expand Azenta's biorepository capabilities. On a pro forma basis, the acquisition is expected to dilute 2026 Adjusted EBITDA margin by 35 basis points, while being accretive to 2027 and 2028 organic revenue growth and Adjusted EBITDA margin expansion.

• ·Conference call and webcast scheduled for March 10, 2026 at 10:00 am Eastern Time; replay available March 11, 2026.
• ·UK Biocentre founded in 2014.
• ·Azenta headquartered in Burlington, MA, with operations in North America, Europe, and Asia.

04-03-2026

KALA BIO, Inc. announced a strategic initiative to deploy an on-premises AI infrastructure platform 'Researgency' for the biotech industry, entering into a Platform Development and Exclusive License Agreement with Younet AI (2624465 Ontario Inc.) for an exclusive worldwide license in biotechnology for an initial 12-month term with renewal options. The company will first apply it internally to its MSC-S biological datasets and KPI-012 clinical program before scaling to external clients via a platform-as-a-service model to generate recurring revenue. This targets an underserved market where the top 20 pharmaceutical companies invested $167B in R&D in 2024, with AI drug discovery spending projected to grow from $4B in 2025 to $25B by 2030.

• ·Exclusive worldwide license for Researgency in biotechnology field
• ·Initial 12-month term with successive 12-month renewal options at KALA's discretion
• ·Phased rollout: Phase 1 internal validation on KALA data; Phase 2 external licensing; Phase 3 platform expansion
• ·Over 3,200 US biotech companies as potential addressable market for on-premises AI
• ·Younet AI experience deploying 100+ custom AI agents across sectors

04-03-2026

Regional Health Properties, Inc. and Erin Property Holdings, LLC entered into Forbearance Agreements with Cadence Bank, N.A. on February 27, 2026 (effective February 1, 2026) due to defaults on the USDA Note ($5M principal) and SBA Note ($800K principal), both due July 27, 2036. The agreements require immediate payments of $21,047.76 (one-time forbearance) and $6,764.21 (USDA renewal fee), with monthly principal and interest payments during the Forbearance Period ending February 1, 2027, after which full balances including late fees are due. This provides temporary relief from remedies but highlights ongoing payment defaults and obligations.

• ·Forbearance Agreements attached as Exhibits 10.1 (USDA Note) and 10.2 (SBA Note).
• ·Notes issued pursuant to Security Agreement dated July 27, 2011.
• ·During Forbearance Period, interest continues to accrue per original Note terms.

04-03-2026

AmBase Corporation entered into a Litigation Funding Agreement (RAB 2026 LFA) with CEO Richard A. Bianco for up to $6M to fund operations and the 111 West 57th Property litigation, including conversion of $4M existing promissory notes and $2M in new cash infusions. BARC Investments LLC simultaneously converted its $2M note (plus ~$200k accrued interest) into a pari-passu LFA (BARC 2026 LFA). However, these deals dilute future litigation proceeds significantly, with funders prioritized for up to 1.8x multiples on funding amid persistent going concern qualifications and uncertain litigation outcomes requiring additional capital.

• ·Accrued interest on RAB and BARC notes matures in 3 years from end of execution month.
• ·Funding approved by Special Committee of one independent director, advised by outside counsel.
• ·Litigation funding terms evaluated as fair despite prior unsuccessful third-party funding search.
• ·Company continues to seek additional capital; no assurance of success or litigation recovery.

04-03-2026

Unknown Company disclosed via 8-K the execution of an Indenture dated February 26, 2026, between VCP RRL ABS V, LLC (Issuer) and State Street Bank and Trust Company (Trustee), governing the issuance of Secured Notes and Class A-L Loans. The Notes are secured by Collateral Obligations (listed in Schedule 1), Accounts, Eligible Investments, and related agreements including the Collateral Management Agreement, Loan Sale Agreement, and Class A-L Credit Agreement. No specific issuance amounts or financial performance metrics were detailed in the filing.

• ·Filing Date: March 04, 2026
• ·8-K Items: 1.01 (Entry into Material Definitive Agreement), 2.03 (Creation of Direct Financial Obligation), 9.01 (Exhibits)
• ·Collateral includes Schedule 1 Collateral Obligations, Accounts, Eligible Investments, and proceeds thereof

04-03-2026

At the Jack in the Box Inc. annual shareholder meeting on February 27, 2026, all ten director nominees were elected and four proposals passed, including ratification of KPMG LLP as auditors for FY ending September 27, 2026 (87% support), advisory approval of executive compensation, amendment to the 2023 Omnibus Incentive Plan to increase shares available (62% support), and ratification of the Stockholder Protection Rights Agreement extending it to July 1, 2028. However, significant shareholder opposition was evident, with say-on-pay receiving only 65% support, the incentive plan amendment 62%, the Rights Agreement 70%, and director David Goebel facing a near-split vote (46% for vs 46% against).

• ·All director elections used plurality voting, allowing election despite opposition (e.g., David Goebel: 7,171,171 For, 7,010,617 Against, 1,213,528 Abstain)
• ·Broker non-votes: 561,088 across proposals 3-5

04-03-2026

On March 2, 2026, Alignment Healthcare, Inc. entered into an underwriting agreement with J.P. Morgan Securities LLC and a selling stockholder for the underwritten offering of 13,167,733 shares of the Company's common stock. The offering closed on March 4, 2026, pursuant to a Registration Statement on Form S-3ASR (File No. 333-293928) filed that day, with the Company receiving no proceeds from the sale. The agreement includes customary representations, warranties, covenants, and indemnification obligations.

• ·Registration Statement File No. 333-293928 filed March 2, 2026
• ·Common stock par value $0.001 per share, traded as ALHC on NASDAQ

04-03-2026

Smith Micro reported Q4 FY2025 revenue of $4.0M, down 20% YoY from $5.0M, and FY2025 revenue of $17.4M, down 16% YoY from $20.6M, with gross margins improving slightly to 76.4% and 74.1% respectively. GAAP net losses narrowed to $4.7M ($0.20/share) in Q4 from $4.4M ($0.25/share) and to $30.1M ($1.46/share) for FY from $48.7M ($3.94/share), with non-GAAP losses also improving. William W. Smith Jr. is transitioning to Executive Chairman at month-end, with Tim Huffmyer becoming President and CEO, supported by $4M funding from Smith and his wife.

• ·Total assets declined to $25.0M as of Dec 31, 2025 from $48.0M as of Dec 31, 2024.
• ·Goodwill fully impaired to $0 as of Dec 31, 2025 from $11.1M as of Dec 31, 2024.
• ·Accounts receivable net declined to $1.8M as of Dec 31, 2025 from $5.7M as of Dec 31, 2024.
• ·Reverse stock split (1-for-8) effective April 10, 2024.
• ·Investor conference call on March 4, 2026 at 4:30 p.m. ET.

04-03-2026

Emmaus Life Sciences, Inc. entered into an Exclusive Supply Agreement with NeoImmuneTech, Inc. on March 2, 2026, as contemplated by the prior License and Exclusive Distribution Agreement dated December 24, 2025, granting NIT exclusive rights to market, sell, and distribute Endari® and generic equivalents for sickle cell disease in the U.S., its territories, and Canada. Under the Supply Agreement, Emmaus will exclusively supply the products to NIT at cost plus a specified double-digit percentage margin, subject to the License Agreement's Effective Date. However, the Effective Date depends on NIT obtaining necessary regulatory approvals and other conditions, with no assurance of occurrence and potential termination by either party if not achieved by October 1, 2026.

• ·License Agreement previously reported in 8-K filed December 31, 2025
• ·Field: sickle cell disease
• ·Territory: U.S. and its territories/possessions, Canada
• ·Full agreements to be filed as exhibits to 10-K for year ended December 31, 2025 and 10-Q for three months ended March 31, 2026

04-03-2026

Applied Digital Corporation entered into an unconditional guarantee effective February 26, 2026, backing the full performance obligations of its subsidiary Base Electron, Inc. under a Design-Build Agreement with The Babcock & Wilcox Company. The guarantee covers both monetary and non-monetary obligations, remains in effect until all obligations are discharged, and includes waivers of typical surety defenses. No specific financial amounts or terms of the underlying Design-Build Agreement were disclosed.

• ·Guarantee governed by Texas law with exclusive jurisdiction in Texas courts.
• ·Payments under guarantee due within 30 days of written demand.
• ·Notice addresses: Applied Digital at 3811 Turtle Creek Blvd., Suite 2100, Dallas, TX 75219; Babcock & Wilcox at 1200 East Market Street, Suite 650, Akron, OH 44305.

04-03-2026

BrightSpring Health Services, Inc. entered into an underwriting agreement on March 2, 2026, with Goldman Sachs & Co. LLC for the secondary offering of 20,000,000 shares of common stock by selling stockholders KKR Phoenix Aggregator L.P. and Management Selling Stockholders at $41.15 per share (totaling $823M), with closing on March 4, 2026. The company repurchased 1,464,807 shares from the underwriter as part of the offering and received no proceeds except from cash exercises of stock options by management sellers. No underwriting fees were paid on the repurchased shares.

• ·Underwriting agreement filed as Exhibit 1.1
• ·Registration statement on Form S-3ASR (File No. 333-287916) filed June 10, 2025
• ·Preliminary prospectus supplement filed March 2, 2026; final March 3, 2026

04-03-2026

On February 26, 2026, Dror Ortho-Design, Inc. entered into a Securities Purchase Agreement for a private placement, selling debentures with an aggregate principal amount of $200,000, bearing 0% interest and due April 27, 2026. The debentures are convertible into common stock upon consummation of a public offering at the offering price, subject to a 9.99% beneficial ownership limit, with potential issuance of warrants equal to 100-150% of related shares depending on timing. The transaction was consummated for $200,000 and exempt from registration under Section 4(a)(2) and Regulation D.

• ·Debentures maturity date: April 27, 2026, extendable by holder in 60-day increments.
• ·Warrants, if issued, exercisable immediately at Public Offering price, expire 5 years from issuance.
• ·Filing date: March 04, 2026; event date: February 26, 2026.

04-03-2026

PennantPark Floating Rate Capital Ltd. entered into a Second Supplemental Indenture with Equiniti Trust Company, LLC, for the issuance of $200M aggregate principal amount of 6.75% notes due 2029, generating net proceeds of approximately $195.9M after underwriting discounts and expenses. The Company intends to use the proceeds to repay outstanding indebtedness under its multi-currency senior secured revolving credit facility with Truist Bank and other lenders, invest in portfolio companies, and for general corporate purposes. The notes are general unsecured obligations, ranking pari passu with existing unsecured debt but effectively subordinated to secured indebtedness.

• ·Notes mature on March 4, 2029, with interest payable semi-annually on March 4 and September 4, commencing September 4, 2026.
• ·Base Indenture dated March 23, 2021; credit facility initially entered August 12, 2021.
• ·Indenture includes covenants for compliance with Investment Company Act asset coverage requirements and change of control repurchase at 100% principal plus accrued interest.
• ·Notes offered under Registration Statement on Form N-2 (File No. 333-279726); prospectus supplements dated February 25, 2026.

04-03-2026

H2O America (NASDAQ: HTO) announced a proposed underwritten public offering of $550M in common stock, consisting of $150M direct issuance by the company and $400M via forward sale agreements with JPMorgan and Wells Fargo affiliates, with a 30-day underwriter option for up to $82.5M additional shares. Net proceeds, along with debt financing, are intended primarily to fund the Quadvest Acquisition and related expenses, or for general corporate purposes if the acquisition does not close, as the offering is not conditioned on it. The announcement highlights no immediate financial metrics but notes risks including regulatory approvals and integration challenges for the acquisition.

• ·Announcement date: March 2, 2026
• ·Filing date: March 4, 2026
• ·Forward sale agreements settlement by March 2, 2028 at company's discretion
• ·Underwriter option period: 30 days
• ·Operates across approximately 409,000 water and wastewater service connections serving 1.6 million people

04-03-2026

Sabre GLBL Inc., a wholly owned subsidiary of Sabre Corporation, completed the redemption of all $91.6M aggregate principal amount of its 8.625% Senior Secured Notes due 2027 on March 1, 2026, at a redemption price of 102.156% of the principal plus accrued and unpaid interest. This redemption, as previously announced on December 23, 2025, terminates the related Indenture dated September 7, 2023, with Computershare Trust Company, N.A. as trustee.

• ·Indenture dated September 7, 2023
• ·Redemption notice provided December 23, 2025

04-03-2026

Farmer Brothers Coffee Co. (NASDAQ: FARM) will be acquired by Royal Cup Coffee & Tea for $1.29 per share in an all-cash transaction, creating a scaled, integrated beverage solutions platform with support from Braemont Capital. The deal has unanimous board approval and is expected to close by June 30, 2026, subject to shareholder approval and customary conditions, after which FARM will become private and delist from NASDAQ. No period-over-period financial metrics were disclosed in the announcement.

• ·Transaction expected to close in fiscal fourth quarter ending June 30, 2026.
• ·Farmer Brothers founded in 1912; Royal Cup nearly 130 years old (since 1896).
• ·Proxy statement to be filed with SEC; shareholders urged to read for details.

04-03-2026

On March 4, 2026, Charging Robotics Inc. entered into a securities purchase agreement with accredited investors for a private placement of 500,000 shares of common stock or pre-funded warrants at $4.00 per share or $3.9999 per pre-funded warrant, expecting approximately $2.0 million in gross proceeds before expenses. The transaction is expected to close upon the effectiveness of the company's uplisting to a national securities exchange, subject to customary conditions. A registration rights agreement requires filing a resale registration statement with the SEC within 30 days post-closing.

• ·Pre-Funded Warrants exercisable at $0.0001 per share and do not expire until fully exercised.
• ·Resale Registration Statement must be declared effective within 60 days (if not reviewed by SEC) or 90 days (if reviewed) after filing.
• ·Securities offered pursuant to Section 4(a)(2) of the Securities Act exemption.
• ·Company is an emerging growth company.

04-03-2026

Hess Midstream LP announced a $60M accretive repurchase, consisting of $18M (455,811 Class B units at $39.49 each) from a Chevron affiliate via its subsidiary Hess Midstream Operations LP, and $42M of Class A shares through an accelerated share repurchase (ASR) agreement with JPMorgan Chase Bank. The transactions, unanimously approved by the conflicts committee, are expected to boost distributable cash flow per Class A share, supporting at least 5% annual distribution growth through 2028, while preserving approximately $1B in financial flexibility. Funding will come from the existing revolving credit facility, with unit repurchase closing on March 4, 2026, and ASR settling in March 2026.

• ·Unit repurchase represents approximately 0.2% of the consolidated company.
• ·Post-unit repurchase (pre-ASR): ownership 62.2% public and 37.8% Chevron.
• ·ASR final shares based on volume-weighted average prices during term.
• ·Transactions unanimously approved by Board based on conflicts committee recommendation.

04-03-2026

Aquestive Therapeutics reported Q4 2025 total revenues of $13.0M, up 10% YoY from $11.9M, driven by manufacture and supply revenue growth to $12.0M, while FY 2025 revenues declined 3% to $44.5M excluding prior-year deferred revenue recognition, with manufacture and supply revenue flat at $40.2M. Net losses widened significantly to $31.9M in Q4 (incl. $13.6M one-time legal) and $83.8M for FY 2025 (incl. $14.3M one-time legal), versus $17.1M and $44.1M prior year, due to higher SG&A and commercial spending for Anaphylm launch prep; however, the company met 2025 guidance excluding one-time items and guides to $70M cash at end-FY2026. Pipeline updates include Anaphylm NDA resubmission targeted for Q3 2026 post-CRL, with RTW revenue sharing extended to June 30, 2027, a $5M share purchase commitment, and warrant for 375,000 shares.

• ·CRL received Jan 30, 2026 for Anaphylm NDA (human factors/PK issues, no CMC/clinical concerns)
• ·RTW agreements dated March 3, 2026: revenue sharing extension to June 30, 2027; warrant exercise price $4.00 expiring March 3, 2029; $5M share purchase in 90 days
• ·Libervant tentatively approved until Jan 2027 (orphan exclusivity expiration)
• ·AQST-108 IND opened Dec 2025; Phase 1 dosing complete Q1 2026
• ·Confidential settlement with Neurelis Dec 2025; 2026 cash impact same/lower than prior forecast
• ·Conference call March 5, 2026

04-03-2026

Diversified Energy Company (NYSE: DEC, LSE: DEC) announced the execution of a purchase and sale agreement to acquire high-working interest natural gas properties and facilities in east Texas from Sheridan Production for $245M in cash, expected to close in Q2 2026 and funded via existing liquidity. The acquisition adds ~62 MMcfepd (~10 MBoepd) of 2026 production with low ~6% annual declines, ~$52M NTM EBITDA, and ~397 Bcfe PDP reserves at $310M PV-10, at an accretive ~PV-15 net valuation. The assets are contiguous to existing operations, offering synergies, with no declines in consolidated production profile pro forma.

• ·Assets based on NYMEX strip as of February 2, 2026, with terminal prices of $3.75/MMBtu gas and $65/Bbl oil
• ·Expected to maintain unchanged consolidated decline rate pro forma
• ·Includes opportunities for future operating efficiencies and upside from undeveloped acreage

04-03-2026

Viper Energy, Inc. announced the pricing of a secondary public offering of 17,391,304 shares of Class A common stock by Diamondback Energy, Inc. and affiliates of EnCap Investments, L.P. and Oaktree Capital Management, L.P., generating approximately $798M in gross proceeds solely for the selling stockholders, with Viper receiving no proceeds. Concurrently, Viper agreed to purchase 1,000,000 units in VNOM Holding Company LLC from Oaktree affiliates at the offering price per share equivalent. The offering is expected to close on March 4, 2026, subject to customary conditions, with underwriters granted a 30-day option for up to 2,608,696 additional shares.

• ·Selling Stockholders granted underwriters a 30-day option to purchase up to 2,608,696 additional shares solely for over-allotments.
• ·Concurrent OpCo Unit Purchase is conditioned on Secondary Offering completion, but not vice versa.
• ·J.P. Morgan and Goldman Sachs & Co. LLC acting as joint book-running managers.

04-03-2026

Lithia Motors, Inc. entered into the Seventh Amendment to its Fourth Amended and Restated Loan Agreement on February 27, 2026, extending the credit facility's expiration date to February 27, 2031, with annual 1-year extension options subject to lender consent and conditions. The amendment introduces VIN-specific reporting for Used Vehicle and Service Loaner Floorplan facilities (upon company election) and reallocates commitments to $2.7B for New Vehicle Floorplan, $1.25B for Used Vehicle Floorplan, $150M for Service Loaner Floorplan, and $2.4B for Revolving Line of Credit. It also removes the Simple SOFR Adjustment.

• ·Original Loan Agreement dated April 29, 2021
• ·Filing submitted on March 4, 2026

04-03-2026

Genesis Energy, L.P. and Genesis Energy Finance Corporation closed a $750 million offering of 6.750% senior notes due May 15, 2034, on March 4, 2026, following the Underwriting Agreement dated February 18, 2026. Net proceeds will fund the redemption of all outstanding 7.75% senior notes due 2028 and general partnership purposes, including partial repayment of revolving borrowings under the senior secured credit facility. The new notes are senior unsecured obligations ranking equal with existing senior debt totaling $2.4 billion across maturities from 2029 to 2033.

• ·Interest on new notes accrues at 6.750% per year, payable semi-annually on March 15 and September 15, commencing September 15, 2026.
• ·Indenture governed by Base Indenture dated May 21, 2015, supplemented by Twenty-Fourth Supplemental Indenture dated March 4, 2026.

04-03-2026

Walker & Dunlop, Inc. and Walker & Dunlop, LLC entered into the Seventeenth Amendment to their Second Amended and Restated Warehousing Credit and Security Agreement with PNC Bank, effective March 2, 2026, extending the Warehousing Maturity Date to March 1, 2027. The amendment permits incremental increases to the Standard Warehousing Credit Limit in $100M minimum increments (each for 45 days) up to the Maximum Warehousing Credit Limit and a one-time Limited Bulge Increase up to $2.5B USD through May 1, 2026, subject to Lender discretion. Associated fees include an annual 10 basis points on the Standard Limit, $10,000 per $100M incremental increase, and a daily 7.5 basis points bulge commitment fee.

• ·Incremental increases to Standard Warehousing Credit Limit effective for 45 days each
• ·Limited Bulge Increase available from March 2, 2026 to May 1, 2026
• ·Original Credit Facility Agreement dated September 11, 2017, with 16 prior amendments listed

04-03-2026

Designer Brands Inc. and its subsidiaries entered into a Third Amendment to their Credit Agreement on February 27, 2026, with The Huntington National Bank as Administrative Agent, primarily to extend the Maturity Date and amend certain provisions of the existing agreement originally dated March 30, 2022. The amendment's effectiveness is conditioned on, among other things, a Borrowing Base Certificate demonstrating Availability of no less than $90,000,000 as of January 31, 2026, confirmation of no Defaults or Events of Default, and no Material Adverse Effect since November 30, 2025. All Loan Documents are ratified and reaffirmed.

• ·Previous amendments: First Amendment on February 28, 2023; Joinder and Second Amendment on June 23, 2023.
• ·Conditions include recent lien searches revealing no impermissible Liens, favorable legal opinions from Vorys, Sater, Seymour and Pease LLP and Osler, Hoskin & Harcourt LLP, and payment of fees per Third Amendment Fee Letter.
• ·Governing law: State of New York.

04-03-2026

Franklin Street Properties Corp. (FSP) closed a $320M secured credit facility with an affiliate of TPG Credit, using an initial $258.5M drawdown (net of $16.5M original issue discount) to fully repay $248.9M of outstanding indebtedness, with up to $45M available in delayed draw term loans for tenant improvements and other uses. The facility features a 9.0% initial coupon rate, 4.0% exit fee, and maturity on February 26, 2029, secured by a first priority lien on substantially all assets. Management highlighted the refinancing as addressing near-term debt maturities amid an uneven office market, while continuing review of strategic alternatives to maximize shareholder value.

• ·Facility maturity date: February 26, 2029, with potential one-year extension at company's option subject to conditions.
• ·Collateral: first priority lien on substantially all assets of the Company.
• ·Core markets: Dallas, Denver, Houston, and Minneapolis.

04-03-2026

Cooper-Standard Holdings Inc.'s subsidiary, Cooper-Standard Automotive Inc., issued $1.1B aggregate principal amount of 9.250% Senior Secured First Lien Notes due 2031 and entered into related security and intercreditor agreements. Proceeds, along with cash on hand, were used to fully redeem $616.9M of higher-rate 13.50% First Lien Notes due 2027 (at 102.250%), $391.8M of 5.625%/10.625% Third Lien Notes due 2027 (at 101.410%), and $42.6M of 5.625% Senior Notes due 2026 (at 100%). The company also amended its ABL Facility to adjust guarantors and covenants, refinancing shorter-term, higher-cost debt with lower-cost, longer-term obligations.

• ·Notes mature on March 1, 2031; interest payable semi-annually on May 15 and November 15, commencing November 15, 2026.
• ·Optional redemption after March 1, 2028 at par plus premiums; prior redemptions include make-whole premium or up to 35% from equity proceeds or 10% at 103%.
• ·Change of Control requires repurchase offer at 101% of principal.
• ·Indenture includes covenants limiting indebtedness, liens, dividends, investments, affiliates transactions, and asset sales.

04-03-2026

Impact BioMedical Inc. amended its Merger and Share Exchange Agreement dated June 21, 2025, extending the termination date from March 31, 2026, to July 1, 2026, and providing for issuance of 53,000 PubCo ordinary shares (first batch) and 75,000 (second batch) to DSS, Inc., plus 22,000 to CEO Frank D. Heuszel, all deducted from the 169,560,000 shares (94.20% ownership) to be issued to the Dr Ashleys Shareholder at closing. Amendments to the Voting and Support Agreement updated supporting stockholders' ownership to 92,980,843 Impact shares (88.87% on fully diluted basis), and the Transition Arrangement Agreement outlined DSS funding obligations tied to the share issuances. No financial metrics or performance declines were reported.

• ·Merger termination End Date extended to July 1, 2026 (previously March 31, 2026).
• ·Impact required to seek board approval for certain loan agreements prior to Effective Time.
• ·DSS shares issuance subject to effectiveness of registration statement and full performance of funding obligations.

04-03-2026

XWELL, Inc. designated 35,000 shares of Series H Convertible Preferred Stock with a stated value of $1,000 per share (total $35M) and an initial conversion price of $0.47 into common stock, adopted by the Board on February 26, 2026, pursuant to a Securities Purchase Agreement dated February 24, 2026. The preferred stock is immediately convertible at the holder's option, subject to a 4.99% beneficial ownership limitation (increaseable to 9.99%). No financial performance metrics or period comparisons are provided in the filing.

• ·Certificate of Designation filed as EX-3.1 with 8-K on March 04, 2026
• ·Conversion shares issuable: Stated Value divided by Conversion Price
• ·Delivery of conversion shares required within 5 business days
• ·Adjustments to Conversion Price for stock splits, combinations, or reclassifications
• ·No dividends on Series H Preferred Stock unless consented by Required Holders and paid pro rata as-if-converted

04-03-2026

IREN Limited entered into purchase agreements for over 50,000 NVIDIA B300 GPUs, expanding its total AI cloud fleet to 150,000 GPUs with phased deployments through H2 2026 across data centers in Mackenzie, British Columbia, and Childress, Texas. This expansion is projected to support over $3.7B in annualized AI Cloud run-rate revenue by end-2026, backed by $9.3B in secured funding over the past eight months and planned $3.5B additional capex in H2 2026. Figures are illustrative, not fully contracted, and subject to execution risks including timely delivery and contracting.

• ·Deployment phases through H2 2026 in air-cooled data centers at Mackenzie, British Columbia and Childress, Texas; existing capacity at Canal Flats.
• ·Payment terms structured post-shipment for working capital efficiency; procurement sequenced with commercial milestones and capital availability.

04-03-2026

NRG Energy announced the launch of a secondary public offering of 12.3 million shares of its common stock by affiliates of LS Power, with a 30-day underwriter option for an additional 1.845 million shares; NRG will not receive proceeds. Concurrently, NRG entered a stock purchase agreement to repurchase $300 million of its common stock from the selling stockholders at the offering price, pursuant to its existing repurchase program, with closing expected alongside the offering. This follows the January 30, 2026, closing of NRG's acquisition of LS Power portfolio entities.

• ·Underwriters: Barclays and Citigroup as joint book-running managers
• ·Selling Stockholders granted 30-day option to underwriters
• ·Share Repurchase conditioned on Secondary Offering completion, but not vice versa

04-03-2026

Totaligent, Inc. entered into an Extension Amendment on March 4, 2026, to its Binding Letter of Intent dated February 11, 2026, with Aetherium Medical, extending the target date for negotiating definitive agreements and closing the proposed acqui-hire transaction from March 5, 2026, to March 20, 2026. The binding exclusivity period remains unchanged through April 5, 2026. This amendment allows additional time for due diligence and negotiations without altering other LOI terms.

• ·Previous disclosure in Form 8-K filed February 12, 2026
• ·Company address: 3651 FAU Boulevard, Suite 400, Boca Raton, Florida 33431
• ·Telephone: (561) 360-3565

04-03-2026

MAIA Biotechnology, Inc. (NYSE American: MAIA) announced the commencement of an underwritten public offering of common stock and pre-funded warrants, with the underwriters granted a 30-day option to purchase additional shares; the offering is subject to market conditions with no assurance of completion or terms. Konik Capital Partners, LLC (a division of T.R. Winston & Company) serves as the sole book-running manager, and net proceeds will fund clinical trials, working capital, and general corporate purposes. The offering utilizes a shelf registration on Form S-3 effective August 23, 2023.

• ·Shelf registration statement on Form S-3 (File No. 333-273984) filed August 15, 2023, and declared effective August 23, 2023.
• ·Press release dated March 02, 2026; SEC 8-K filing dated March 04, 2026.